https://www.selleckchem.com/pr....oducts/sulfosuccinim
For NAFLD patients, the adjusted odds ratio (aOR) for the severe COVID-19 was 2.60 (95%CI2.24-3.02; p0.001) (studies,n8), aOR for admission to ICU due to COVID-19 was 1.66 (95%CI1.26-2.20; p0.001) (studies,n2), and aOR for mortality for was 1.01 (95%CI0.65-1.58; p=0.96) (studies,n2). An increased risk of severe COVID-19 infection and admission to ICU due to COVID-19 with no difference in mortality was observed between NAFLD and non-NAFLD patients. Future studies should include the mortality outcome to con
Like
Comment
Share
